Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma

Inclusion Criteria: * Pathologically confirmed diagnosis of RCC of any histology. * Be willing and able to undergo biopsy of a lesion planned for definitive RT (such as SBRT) both post treatment and pretreatment. If a lesion amenable to definitive RT was biopsied prior to enrollment, this material can be used in lieu of a planned biopsy if the tissue is available for review and ki-67 staining at MD Anderson. * Patients may be allowed on this trial without a biopsy if they are deemed medically unfit for biopsy or if the biopsy poses undue risk in the opinion of the treating physician(s). * Be \>= 18 years of age on the day of signing informed consent * Eastern Cooperative Oncology Group (ECOG) performance status 0-2. * NOTE: If subject is unable to walk due to paralysis, but is mobile in a wheelchair, subject is considered to be ambulatory for the purpose of assessing their performance status. * COHORT A: Oligometastatic RCC patients (=\< 5 metastatic lesions at the time of study entry). * COHORT B: Patients eligible for Cohort A in addition to low volume metastatic patients. Low volume metastatic patients are defined as those with \> 5 metastatic lesions, but with =\< 5 metastatic lesions when excluding lesions \< 1 cm short axis and LNs \< 1 cm short axis * Candidate for definitive local therapy to all sites of active disease per the discretion of the treating physicians * Absolute neutrophil count (ANC) \>= 1,000 /mcL (within 6 weeks prior to study enrollment). * Pla…